If you have been reading about research compound and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-09-09. Numbers and descriptions here follow the published literature rather than marketing material.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small molecule | Studied as a REV-ERB agonist |
| Molecular formula | C20H24ClN3O4S | Reported for the neutral compound |
| Appearance | Off-white to pale yellow solid | Typical research-grade material |
| Solubility | Sparingly soluble in water | Soluble in solvents such as DMSO |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal alias |
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
=== Withdrawal === Carisoprodol, meprobamate, and related drugs such as tybamate may produce physical dependence of the barbiturate type after prolonged use. Withdrawal after extensive use may require hospitalization in medically compromised patients. In severe cases the withdrawal can mimic the symptoms of alcohol withdrawal, including the potentially lethal status epilepticus. Psychological dependence has also been linked to carisoprodol use. Psychological dependence is more common in those who use carisoprodol non-medically and those who have a history of substance use (particularly sedatives or alcohol). It may reach clinical significance before physiological tolerance and dependence have occurred and (as with benzodiazepines) has been demonstrated to persist in varying degrees of severity for months or years after discontinuation. Discontinuation of carisoprodol, as with all GABA-ergics, can result in cognitive changes that persist for weeks, months, or rarely even years, including greatly increased anxiety and depression, social withdrawal, hair-trigger agitation/aggression, chronic insomnia, new or aggravated (often illogical) phobias, reduced IQ, short- and long-term memory loss, and dozens of other sequelae. The effects, severity, and duration appear to be slightly dose-dependent but are mainly determined by the patient's pattern of use (taken as prescribed, taken in bulk doses, mixed with other drugs, a combination of the above, etc.).
==== Vitamin D2 ==== Plants Alfalfa (Medicago sativa subsp. sativa), shoot: 4.8 μg (192 IU) vitamin D2, 0.1 μg (4 IU) vitamin D3 Fungus, from USDA nutrient database, per 100 g: Mushrooms, portabella, exposed to ultraviolet light, raw: Vitamin D2: 11.2 μg (446 IU) Mushrooms, portabella, exposed to ultraviolet light, grilled: Vitamin D2: 13.1 μg (524 IU) Mushrooms, shiitake, dried: Vitamin D2: 3.9 μg (154 IU) Mushrooms, shiitake, raw: Vitamin D2: 0.4 μg (18 IU) Mushrooms, portabella, raw: Vitamin D2: 0.3 μg (10 IU) Mushroom powder, any species, illuminated with sunlight or artificial ultraviolet light sources Vitamin D2, or ergocalciferol is found in fungus (except alfalfa which is a plantae) and created from viosterol, which in turn is created when ultraviolet light activates ergosterol (which is found in fungi and named as a sterol from ergot). Any UV-irradiated fungus including yeast form vitamin D2. Human bioavailability of vitamin D2 from vitamin D2-enhanced button mushrooms via UV-B irradiation is effective in improving vitamin D status and not different from a vitamin D2 supplement according to study. For example, vitamin D2 from UV-irradiated yeast baked into bread is bioavailable. By visual assessment or using a chromometer, no significant discoloration of irradiated mushrooms, as measured by the degree of "whiteness", was observed making it hard to discover if they have been treated without labeling. Claims have been made that a normal serving (approx.
=== Fortified foods === Foods for which vitamin B12-fortified versions are available include breakfast cereals, plant-derived milk substitutes such as soy milk and oat milk, energy bars, and nutritional yeast. The fortification ingredient is cyanocobalamin. Microbial fermentation yields adenosylcobalamin, which is then converted to cyanocobalamin by the addition of potassium cyanide or thiocyanate in the presence of sodium nitrite and heat. As of 2019, nineteen countries require food fortification of wheat flour, maize flour, or rice with vitamin B12. Most of these are in southeast Africa or Central America. Vegan advocacy organizations, among others, recommend that every vegan consume B12 from either fortified foods or supplements.
Sources: en.wikipedia.org
===== Factors ===== There are many factors that can go into what makes an applicant more or less competitive. According to a survey of residency program directors by the NRMP in 2020, the following five factors were mentioned by directors over 75% of the time as having the most impact:
=== Available forms === Tiagabine is available in the form of 2, 4, 5, 10, 12, 15, and 16 mg oral tablets. The drug is taken 1 to 4 times per day due to its short elimination half-life. A sustained-release formulation would be advantageous but has not been developed or marketed.
On 4 February 2020, US Secretary of Health and Human Services Alex Azar published a notice of declaration under the Public Readiness and Emergency Preparedness Act for medical countermeasures against COVID‑19, covering "any vaccine, used to treat, diagnose, cure, prevent, or mitigate COVID‑19, or the transmission of SARS-CoV-2 or a virus mutating therefrom", and stating that the declaration precludes "liability claims alleging negligence by a manufacturer in creating a vaccine, or negligence by a health care provider in prescribing the wrong dose, absent willful misconduct". The declaration is effective in the United States through 1 October 2024. In the European Union, the COVID‑19 vaccines are licensed under a Conditional Marketing Authorisation which does not exempt manufacturers from civil and administrative liability claims. While the purchasing contracts with vaccine manufacturers remain secret, the manufacturers remain liable even for side-effects not known at the time of licensure. Pfizer has been criticised for demanding far-reaching liability waivers and other guarantees from countries such as Argentina and Brazil, which go beyond what was expected from other countries such as the US (above).
Sources: en.wikipedia.org
The three substrates of this enzyme are aromadendrin ((+)-dihydrokaempferol), reduced nicotinamide adenine dinucleotide phosphate (NADPH), and a proton. Its products are leucopelargonidin and oxidised NADP+. This enzyme is an oxidoreductase with the systematic name cis-3,4-leucopelargonidin:NADP+ 4-oxidoreductase. Other names in common use include dihydroflavanol 4-reductase (DFR), dihydromyricetin reductase, NADPH-dihydromyricetin reductase, and dihydroquercetin reductase. It participates in flavonoid biosynthesis.
The term thagomizer was coined by Gary Larson in jest. In a 1982 The Far Side comic, a group of cavemen are taught by a caveman lecturer that the spikes on a stegosaur's tail were named "after the late Thag Simmons". The term was picked up initially by Kenneth Carpenter, then a paleontologist at the Denver Museum of Nature and Science, who used the term when describing a fossil at the Society of Vertebrate Paleontology Annual Meeting in 1993. Thagomizer has since been adopted as an anatomical term and is used by the Smithsonian Institution, the Dinosaur National Monument, the book The Complete Dinosaur and the BBC documentary series Planet Dinosaur. The term has also appeared in some scientific papers describing stegosaurs and related dinosaurs.
Combination of MAO-substrate psychedelics with monoamine oxidase inhibitors (MAOIs) can result in overdose and toxicity. Examples of MAOIs that may potentiate psychedelics behaving as MAO-A substrates, such as psilocin, include phenelzine, tranylcypromine, isocarboxazid, and moclobemide, as well as harmala alkaloids like harmine and harmaline and chronic tobacco smoking. An early clinical study of psilocybin in combination with short-term tranylcypromine pretreatment found that tranylcypromine marginally potentiated psilocybin's peripheral effects, including pressor effects and mydriasis, but overall did not significantly modify its psychoactive and hallucinogenic effects, although some of its emotional effects were said to be reduced and some of its perceptual effects were said to be amplified. Psilocin may be metabolized to a minor extent by the cytochrome P450 (CYP450) enzymes CYP2D6 and/or CYP3A4 and appears unlikely to be metabolized by other CYP450 enzymes. The role of CYP450 enzymes in psilocin's metabolism seems to be small, and so considerable drug interactions with CYP450 inhibitors and/or inducers may not be expected. Psilocin's major metabolic pathway is glucuronidation by UDP-glucuronosyltransferase enzymes including UGT1A10 and UGT1A9. Diclofenac and probenecid are inhibitors of these enzymes that theoretically might inhibit the metabolism of and thereby potentiate psilocybin's effects, but no clinical research or evidence on this possible interaction exists. Few other drugs are known to influence UGT1A10 or UGT1A9 function.
Euphoria season 3 was met with a mixed response from critics, with praise limited to the ensemble's acting and the visuals, but criticism of its writing, pacing, characterization, tone, music, and handling of mature subject matter. The critical consensus on review aggregator website Rotten Tomatoes reads, "Euphoria returns with less than the sum of its parts in a disjointed cavalcade of forced narratives that leave its talented cast stranded in the wind." The season has an overall approval rating of 44%, with an average rating of 5.8/10 based on 76 critical reviews. Using a weighted average, Metacritic assigned the season a score of 56 out of 100, based on 27 critics, which it describes as "Mixed or Average". Caryn James wrote for BBC News: "the show has lost its zeitgeisty edge. Euphoria has become a series with very little to say, none of it very audacious or compelling." David Opie of Digital Spy wrote, "Euphoria was a striking, standout coming-of-age drama, but the new season doesn't capture its magic. The show hasn't grown up in the same way that these kids supposedly have." Empire's Al Horner wrote, "some constants remain, the good and bad of Euphoria past. This is still a sumptuously-shot show, not to mention a well-acted one: Zendaya in particular is in formidable form once more, letting glints of sadness surface from beneath Rue's veneer of languid detachment. Less appealing is how the camera still hovers longingly over shots of its female characters' bodies, as one-by-one, Levinson's scripts nudge them into sex work and skimpy costumes.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.
No. SR9009 is frequently mislabeled as a SARM in online discussions, but it does not target androgen receptors. Its known mechanism involves REV-ERB nuclear receptors and circadian-metabolic gene regulation.
Human clinical data are very limited. There is no approved human use, and safety and efficacy in people are not established. Most evidence comes from preclinical models, so effects observed in animals may not apply to humans.
The most common approach is liquid chromatography-tandem mass spectrometry, often after extraction from blood, urine, or tissue. Ultraviolet detection and nuclear magnetic resonance spectroscopy are used mainly for reference material characterization. Isotope-labeled internal standards improve accuracy.